Researchers from the University of British Columbia and the Berlin Institute of Health have developed a topical gene‑editing approach that can correct disease‑causing mutations in human skin tissue maintained in the lab. The method uses lipid nanoparticles—tiny fat‑based carriers—to deliver gene‑editing tools into the upper layers of the skin after a brief laser treatment. In tests, the team was able to edit genes directly within human skin samples and also correct a common mutation linked to autosomal recessive congenital ichthyosis (ARCI) in patient‑derived cells. While still early‑stage, this platform could open the door to future treatments for a range of rare genetic skin conditions.

Salk Institute researchers analyzed immune cells from 110 people and found that genetic differences and life experiences (sickness, vaccination history, environment) impact immune cells differently. The findings help explain why people respond differently to the same infections and treatments, and the study provides a foundation for personalized medicine to prevent disease onset, bolster immune health, or treat infectious diseases, cancers, and other immune disorders.

The American College of Medical Genetics and Genomics (ACMG) announced today that the eighth annual Medical Genetics Awareness Week, sponsored by MyOme, will be held March 10–14, 2026, inviting the public, health professionals, patients, and policymakers to learn more about one of the most rapidly advancing and impactful fields in modern medicine.

Bringing the promise of cell and gene therapies to patients is one of the greatest defining opportunities in, and responsibilities of, modern medicine. To that end, The International Society for Stem Cell Research (ISSCR), in collaboration with the California Institute for Regenerative Medicine (CIRM) and the UCLA Broad Stem Cell Research Center, will host the Summit on Access and Affordability in Cell and Gene Therapies on 20 March 2026.

The summit convenes global leaders to confront scientific, economic, and systematic barriers that may limit patient access to potentially curative cellular medicines. Experts in research, clinical care, policy, market access, economics and patient advocacy will engage in cross-sector dialogue to explore pricing, manufacturing, regulation, and reimbursement strategies.